APA (7th ed.) Citation

JL, B., BS, S., DP, B., & KM, S. (2023). Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625. Frontiers in oncology, 13, 1061502. https://doi.org/10.3389/fonc.2023.1061502

Chicago Style (17th ed.) Citation

JL, Boxerman, Snyder BS, Barboriak DP, and Schmainda KM. "Early Post-bevacizumab Change in RCBV from DSC-MRI Identifies Pseudoresponse in Recurrent Glioblastoma: Results from ACRIN 6677/RTOG 0625." Frontiers in Oncology 13 (2023): 1061502. https://doi.org/10.3389/fonc.2023.1061502.

MLA (9th ed.) Citation

JL, Boxerman, et al. "Early Post-bevacizumab Change in RCBV from DSC-MRI Identifies Pseudoresponse in Recurrent Glioblastoma: Results from ACRIN 6677/RTOG 0625." Frontiers in Oncology, vol. 13, 2023, p. 1061502, https://doi.org/10.3389/fonc.2023.1061502.